Similar articles

• An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.

  Moyad MA. Moyad MA. Semin Urol Oncol. 2001 Nov;19(4):306-16. Semin Urol Oncol. 2001. PMID: 11769882 Review.
• COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.

  Sabichi AL, Lippman SM. Sabichi AL, et al. Semin Oncol. 2004 Apr;31(2 Suppl 7):36-44. doi: 10.1053/j.seminoncol.2004.03.044. Semin Oncol. 2004. PMID: 15179622 Review.
• Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.

  Okajima E, Uemura H, Ohnishi S, Tanaka M, Ohta M, Tani M, Fujimoto K, Ozono S, Okajima E, Hirao Y. Okajima E, et al. Aktuelle Urol. 2003 Jul;34(4):256-8. doi: 10.1055/s-2003-41610. Aktuelle Urol. 2003. PMID: 14566678
• Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

  Basler JW, Piazza GA. Basler JW, et al. J Urol. 2004 Feb;171(2 Pt 2):S59-62; discussion S62-3. doi: 10.1097/01.ju.0000107839.06670.27. J Urol. 2004. PMID: 14713756 Review.
• COX-2 inhibitors: a review.

  Houston AM, Teach SJ. Houston AM, et al. Pediatr Emerg Care. 2004 Jun;20(6):396-9; quiz 400-2. doi: 10.1097/01.pec.0000133618.36861.73. Pediatr Emerg Care. 2004. PMID: 15179150 Review. No abstract available.